CN116548609A - Prebiotic composition and use thereof - Google Patents
Prebiotic composition and use thereof Download PDFInfo
- Publication number
- CN116548609A CN116548609A CN202210103501.7A CN202210103501A CN116548609A CN 116548609 A CN116548609 A CN 116548609A CN 202210103501 A CN202210103501 A CN 202210103501A CN 116548609 A CN116548609 A CN 116548609A
- Authority
- CN
- China
- Prior art keywords
- grape
- probiotic composition
- lactitol
- component
- ferment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 235000013406 prebiotics Nutrition 0.000 title description 10
- 239000006041 probiotic Substances 0.000 claims abstract description 126
- 235000018291 probiotics Nutrition 0.000 claims abstract description 126
- 230000000529 probiotic effect Effects 0.000 claims abstract description 94
- 241000219095 Vitis Species 0.000 claims abstract description 91
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 91
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 91
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 91
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical group OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract description 58
- 239000000832 lactitol Substances 0.000 claims abstract description 58
- 229960003451 lactitol Drugs 0.000 claims abstract description 58
- 235000010448 lactitol Nutrition 0.000 claims abstract description 58
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical group OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 28
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 28
- 238000000855 fermentation Methods 0.000 claims abstract description 27
- 230000004151 fermentation Effects 0.000 claims abstract description 27
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 26
- 229920001202 Inulin Polymers 0.000 claims abstract description 19
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 19
- 229940029339 inulin Drugs 0.000 claims abstract description 19
- 230000001737 promoting effect Effects 0.000 claims abstract description 14
- 230000007413 intestinal health Effects 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 38
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 28
- 229960003180 glutathione Drugs 0.000 claims description 20
- 241000186000 Bifidobacterium Species 0.000 claims description 19
- 108010024636 Glutathione Proteins 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 13
- 241000702462 Akkermansia muciniphila Species 0.000 claims description 11
- 150000003573 thiols Chemical class 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 description 39
- 239000000047 product Substances 0.000 description 21
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 229940038487 grape extract Drugs 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 12
- 235000019674 grape juice Nutrition 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000001974 tryptic soy broth Substances 0.000 description 11
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 10
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 241001593968 Vitis palmata Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000194020 Streptococcus thermophilus Species 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 241001494479 Pecora Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 240000002605 Lactobacillus helveticus Species 0.000 description 4
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940054346 lactobacillus helveticus Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 235000019675 red grape juice Nutrition 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 101000693095 Mus musculus Angiopoietin-related protein 4 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003070 absorption delaying agent Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 102100038423 Claudin-3 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000882908 Homo sapiens Claudin-3 Proteins 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000012442 analytical experiment Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a probiotic composition, which comprises a grape ferment, a first component and a second component. Wherein the first component is lactitol or xylooligosaccharide, and the second component is fructooligosaccharide, xylooligosaccharide or inulin. The first component is different from the second component, and the weight ratio of the grape fermented product, the first component and the second component is 1-2:1-2:1-2. Therefore, the probiotic composition prepared by grape fermentation can be used for promoting intestinal health of a receptor and improving antioxidant capacity of the receptor.
Description
Technical Field
The invention relates to application of a probiotic composition, in particular to application of grape fermentation product in preparing the probiotic composition and application of the probiotic composition in promoting intestinal health of a receptor and improving antioxidant capacity of the receptor.
Background
Probiotics (Probiotics), also known as Prebiotics, probiotics, are polysaccharide components of natural foods that are not easily digested by human enzymes, but can be utilized by Probiotics (Probiotics) in the digestive system (mainly the large intestine) on the growth, expansion and metabolism of the flora to short chain fatty acids (Short Chain Fatty Acids, SFCAs).
According to the international society for probiotics and prebiotics (International Scientific Association for Probiotics and Prebiotics, ISAPP) in the joint declaration of probiotics by Nature report in 2017, it is defined as a "substance that can be selectively utilized by microorganisms symbiotic to a host, thus promoting the health of the host".
In particular, the probiotics can assist in the growth of probiotics and help to inhibit bad bacteria in the intestinal tract. Probiotics in the gut will also metabolize the probiotics to short chain fatty acids, providing the probiotics and host as energy sources.
Disclosure of Invention
In view of the above, the present invention provides a probiotic composition comprising a grape ferment and useful for promoting the growth ability of ackermanni (Akkermansia muciniphila) and promoting intestinal health and/or antioxidant ability of the recipient.
In some embodiments, a probiotic composition includes a grape ferment, a first ingredient, and a second ingredient. The first component is lactitol or xylooligosaccharide, and the second component is fructooligosaccharide, xylooligosaccharide or inulin. Wherein the first component is different from the second component. Wherein, the weight ratio of the grape ferment to the first component to the second component is 1-2:1-2:1-2.
In some embodiments, the probiotic composition comprises a grape ferment, a first component, and a second component in a weight ratio of 2:1:1.
in some embodiments, the probiotic composition is used to promote the growth capacity of ackermanni (Akkermansia muciniphila).
In some embodiments, a prebiotic composition comprises a grape fermentation, lactitol as a first ingredient, and fructooligosaccharides as a second ingredient.
In some embodiments, the use of a grape ferment for preparing a probiotic composition that promotes intestinal health of a recipient, wherein the probiotic composition comprises a grape ferment, lactitol and fructo-oligosaccharides, and the weight ratio of grape ferment, lactitol and fructo-oligosaccharides is 1-2:1-2:1-2.
In some embodiments, promoting intestinal health of the recipient includes promoting growth of probiotics, and the probiotics include ackermanni (Akkermansia muciniphila) and bifidobacteria (bifidobacteria).
In some embodiments, the probiotic composition is used to promote the growth capacity of ackermanni (Akkermansia muciniphila).
In some embodiments, the use of a grape ferment for preparing a probiotic composition that enhances the antioxidant capacity of a recipient, wherein the probiotic composition comprises a grape ferment, lactitol and fructo-oligosaccharides, and the weight ratio of grape ferment, lactitol and fructo-oligosaccharides is 1-2:1-2:1-2.
In some embodiments, the probiotic composition is used to increase the level of sulfur-containing compounds and total glutathione (total Glutathione) in the recipient.
In some embodiments, the sulfur-containing compound is a thiol (Thiols) type compound.
In some embodiments, the prebiotic composition comprises a weight ratio of grape fermentate, lactitol, and fructooligosaccharides of 2:1:1.
in summary, the probiotic composition of any embodiment comprises a grape fermentation, a first component and a second component, wherein the first component is lactitol or xylooligosaccharide, and the second component is fructooligosaccharide, xylooligosaccharide or inulin. And, the probiotic composition has the ability to promote growth of ackermanni (Akkermansia muciniphila). In some embodiments, the grape fermentate may be used to prepare a probiotic composition that promotes intestinal health of the recipient and/or enhances the antioxidant capacity of the recipient, and the probiotic composition includes grape fermentate, lactitol, and fructooligosaccharides. In some embodiments, the probiotic composition may promote probiotic growth. For example, probiotics include ackermanni (Akkermansia muciniphila) and bifidobacteria (bifidobacteria). In some embodiments, the probiotic composition may increase the level of sulfur-containing compounds (e.g., thiols (Thiols) and total glutathione (total Glutathione)) in the recipient.
Drawings
FIG. 1 is a graph of the results of an analytical experiment of the effect of multiple sets of different components on probiotics;
FIG. 2 is a graph of experimental results of analysis of the effect of multiple sets of combinations of probiotics in different proportions on probiotics;
FIG. 3 is a graph of experimental results of the growth capacity of a probiotic composition for Acremonium;
FIG. 4 is a graph of experimental results of the growth capacity of a probiotic composition for bifidobacteria;
FIG. 5 is a graph of the results of analysis of f-thiol (Thiols) content in a subject's blood by a probiotic composition; and
FIG. 6 is a graph of the results of analysis of glutathione (t-GSH) content in a subject's blood by a probiotic composition.
Detailed Description
The probiotic composition comprises a grape ferment, sugar alcohols or saccharides as a first component, and saccharides as a second component, and the first component is different from the second component. The sugar alcohol may be lactitol (lactitol), and the saccharide may be oligosaccharide (Oligosaccharides), dietary fiber, and other polysaccharides such as xylooligosaccharide, fructooligosaccharide (fructooligosaccharides), and Inulin (Inulin). The grape fermented product is prepared by fermenting grape extract obtained from red grape fruit with Yeast (Yeast) and Lactobacillus (Lactobacillus).
In some embodiments, the probiotic composition comprises a grape ferment, lactitol, and a polysaccharide, and the weight ratio of grape ferment, lactitol, and polysaccharide is from 1 to 2:1-2:1-2. Here, the polysaccharide may be fructo-oligosaccharide, xylo-oligosaccharide or inulin. For example, the weight ratio of grape fermentate, lactitol and polysaccharide is 2:1:1.
in some embodiments, the probiotic composition comprises grape fermentate, xylo-oligosaccharides and polysaccharides, and the weight ratio of grape fermentate, xylo-oligosaccharides and polysaccharides is 1-2:1-2:1-2. Here, the polysaccharide may be fructo-oligosaccharide or inulin. For example, the weight ratio of grape fermentate, xylo-oligosaccharides and polysaccharides is 2:1:1.
in some embodiments, the probiotic composition comprises a grape ferment, lactitol and fructo-oligosaccharide, and the weight ratio of grape ferment, lactitol and fructo-oligosaccharide is 1-2:1-2:1-2. For example, the prebiotic composition comprises, by weight, 2:1:1, lactitol and fructooligosaccharides.
In some embodiments, the grape fermentate preparation process is: preparing grape extract, implanting a plurality of strains into the grape extract, and standing for culturing.
The grape extract may be red grape juice obtained by squeezing red grape (Vits vinifera) fruit, concentrated grape juice obtained by concentrating red grape juice, grape juice diluted solution obtained by diluting red grape juice or concentrated grape juice, or grape juice obtained by extracting red grape fruit with a solvent.
For example, red grape fruit is directly crushed and filtered to form a grape extract. In some embodiments, the red grape fruit comprises pericarp, pulp, and seed. In some embodiments, the grape extract may be blended with water using commercially available concentrated grape juice. In some embodiments, the grape extract may be blended from concentrated grape juice, water, and glucose. In some embodiments, the grape extract may be prepared using concentrated grape juice, water, and glucose heated above 95 ℃ for 30 minutes. Wherein the volume ratio of the concentrated grape juice to the water can be 1:8. Further, the concentration of glucose may be 3% (W/V), or an amount of glucose such that the Brix degree (Brix DEG) of the glucose extract is 8 or more may be added. That is, the brix of the solution is measured simultaneously during the addition of glucose, and when the brix of the grape extract reaches 8 or more, the addition of glucose is stopped. In some embodiments, the red grape may be a red grape using Sang Jiaowei plug (sangiovres), blue cloth Lu Sike (Lambrusco), or a mixture thereof.
The plurality of species includes yeast (yeast) and lactic acid bacteria (Lactobacillus).
In some embodiments, the grape fermentation may be prepared by planting 0.1% (W/V) yeast and 0.05% (W/V) lactobacillus in grape extract, and then standing for culturing. In some embodiments, the grape fermentation product may be obtained by mixing 0.1% (W/V) yeast and 0.05% (W/V) lactobacillus in grape extract, standing, concentrating under reduced pressure, and/or filtering. In other words, the grape fermentation product may be an initial solution obtained by culturing the grape extract and a plurality of strains, a concentrated solution obtained by concentrating the initial solution under reduced pressure, a filtrate obtained by filtering the initial solution, or a concentrated filtrate obtained by concentrating and filtering the initial solution under reduced pressure.
Wherein the time for culturing the grape extract and the plurality of species may be 72 hours. Furthermore, the temperature of the grape extract and the culture of the plurality of species may be 30 ℃.
Wherein the temperature during the concentration under reduced pressure can be 55-65 ℃.
Wherein the yeast may be Saccharomyces cerevisiae (Saccharomyces cerevisiae). For example, the lager brewing yeast may be lager brewing yeast deposited in the taiwan food industry development institute of biological resource conservation and research center (BCRC) and deposited with strain BCRC20271, which is also deposited in the german collection of microorganisms and cell culture (DSMZ) and international deposit number ATCC33107, or other commercially available lager brewing yeasts.
Wherein the lactobacillus can be Streptococcus thermophilus (Streptococcus thermophilus), lactobacillus helveticus (Lactobacillus helveticus), or Lactobacillus plantarum (Lactobacillus plantarum). For example, the lactic acid bacteria may be streptococcus thermophilus TCI633 (which is also registered with the DSMZ and international registration number DSM 28121) registered with BCRC and registration number BCRC910636, lactobacillus helveticus TCI357 (which is also registered with the DSMZ and international registration number DSM 33107) registered with BCRC910846, streptococcus thermophilus TCI028 (which is also registered with the DSMZ and international registration number DSM 33108) registered with BCRC910805, streptococcus thermophilus TCI378 (which is also registered with the DSMZ and international registration number DSM 32451) registered with BCRC910760, other commercially available streptococcus thermophilus, other commercially available lactobacillus helveticus, or other commercially available lactobacillus plantarum.
For example, a concentrated juice of red grape is blended with water to form a grape juice solution. Wherein the volume ratio of the concentrated juice to the water is 1:8. Next, 3% (W/V) glucose was added to the grape juice solution and allowed to stand at 95℃for 0.5 hours to obtain a grape extract. Then, 0.1% (W/V) of Saccharomyces cerevisiae and 0.05% (W/V) of Streptococcus thermophilus TCI633 were implanted into the obtained grape extract and subjected to stationary culture at 30℃for 72 hours to obtain a grape fermentation primary liquid. And concentrating the grape fermentation primary liquid at 60 ℃ under reduced pressure, and filtering the grape fermentation primary liquid after concentrating under reduced pressure by using a pore size of 400mesh to obtain a grape fermentation product.
Thus, the probiotic composition may be obtained by mixing the fermentation product of the grape obtained by a specific process, lactitol or xylo-oligosaccharide as a first component, and fructo-oligosaccharide, xylo-oligosaccharide or inulin as a second component in a specific ratio. Wherein, the weight ratio of the grape ferment to the first component to the second component is 1-2:1-2:1-2. Also, the probiotic composition may increase the bacterial load of probiotics such as ackermann bacteria (Akkermansia muciniphila) in the recipient's intestinal tract.
In some embodiments, a probiotic composition comprising a grape ferment, lactitol, and fructooligosaccharides may be used to promote intestinal health in a recipient. For example, the probiotic composition may increase the bacterial load of ackermanni in the recipient gut by at least 2.5-fold and increase the bacterial load of bifidobacteria (bifidobacteria) by at least 3.8-fold. Thus, the probiotic composition can improve intestinal bacterial phase, thereby achieving the effect of promoting the intestinal health of the receptor.
In some embodiments, a probiotic composition comprising a grape ferment, lactitol, and fructooligosaccharides increases the antioxidant capacity of the recipient. For example, the probiotic composition may increase the level of sulfur-containing compounds, the level of total glutathione (total Glutathione), or a combination thereof in the recipient. In some embodiments, the sulfur-containing compound is a thiol (Thiols) type compound. The ability of the receptor to scavenge free radicals can be increased by increasing the sulfur-containing compounds and/or total glutathione, thereby enhancing resistance to oxidative stress from cell damage.
In some embodiments, the probiotic composition may be in a solid state, e.g., a powder, lozenge, capsule, or the like.
In some embodiments, the dose of the probiotic composition is 400 mg/day. For example, a probiotic composition is mainly composed of grape fermentate, lactitol and fructo-oligosaccharides, whereas a daily dose of 400mg of the probiotic composition means that the total amount of grape fermentate, lactitol and fructo-oligosaccharides is 400mg.
Any of the aforementioned probiotic compositions may be a pharmaceutical. In other words, the pharmaceutical product comprises an effective amount of a fermentation product of grape, lactitol or xylo-oligosaccharide as a first component, and fructo-oligosaccharide, xylo-oligosaccharide or inulin as a second component, which are composed in a specific ratio.
In some embodiments, the aforementioned medicaments may be manufactured using techniques well known to those skilled in the art as suitable for enteral, parenteral (paremetric), oral, or topical (topicaly) administration dosage forms.
In some embodiments, the dosage form for enteral or oral administration may be, but is not limited to, a tablet, a troche, a pill, a capsule, a dispersible powder, a granule, a solution, a suspension, an emulsion, a syrup, an elixir, a slurry, or the like. In some embodiments, the parenteral or topical dosage form may be, but is not limited to, an injectable, sterile powder, external preparation (external preparation) or the like. In some embodiments, the administration of the injectate can be subcutaneous injection (subcutaneous injection), intradermal injection (intraepidermal injection), intradermal injection (intradermal injection), or intralesional injection (intralesional injection).
In some embodiments, the aforementioned pharmaceuticals may comprise a pharmaceutically acceptable carrier (pharmaceutically acceptable carrier) that is widely used in pharmaceutical manufacturing technology. In some embodiments, the pharmaceutically acceptable carrier may be one or more of the following: solvents (solvents), buffers (buffers), emulsifiers (suspending agents), disintegrants (decomponents), disintegrants (disintegrating agent), dispersants (dispersing agents), binders (binding agents), excipients (excipients), stabilizers (stabilizing agent), chelating agents (chelating agents), diluents (diluents), gelling agents, preservatives (solvents), wetting agents (lubricants), lubricants (absorption delaying agent), absorption retarders (absorption delaying agent), liposomes (lipomes), and the like. The type and number of carriers selected will be within the purview of those skilled in the art of expertise and routine skill. In some embodiments, the solvent as a pharmaceutically acceptable carrier may be water, normal saline (normal saline), phosphate buffered saline (phosphate buffered saline, PBS), or an aqueous solution containing alcohol (aqueous solution containing alcohol).
In some embodiments, any of the foregoing probiotic compositions may be an edible product. In other words, the edible product comprises a specific content of a fermentation of grape, a lactitol or a xylo-oligosaccharide as a first component, and a fructo-oligosaccharide, a xylo-oligosaccharide or a inulin as a second component, which are composed in a specific ratio. In some embodiments, the edible product may be a general food, a health food, or a dietary supplement.
In some embodiments, the foregoing edible products may be manufactured into dosage forms suitable for oral administration using techniques well known to those skilled in the art. In some embodiments, the aforementioned general food product may be the edible product itself. In some embodiments, the general food product may be, but is not limited to: beverages (beverages), fermented foods (fermented foods), bakery products (bakery products) or seasonings.
In some embodiments, the resulting probiotic composition may be further used as a food additive (food additive) to produce a food composition comprising a fermentation of grape, lactitol or xylo-oligosaccharide as a first component, and fructo-oligosaccharide, xylo-oligosaccharide or inulin as a second component. The probiotic composition of any embodiment can be added during the preparation of the raw materials by the prior method, or the probiotic composition of any embodiment can be added during the preparation of the food, and the probiotic composition and any edible material can be prepared into edible products (i.e. food compositions) for ingestion by human beings and non-human animals.
Example 1: preparation of grape ferment
First, a concentrated juice of red grape from the Italy Sang Jiaowei plug (Sangioviese) was blended with water to form a grape juice solution. Wherein the volume ratio of the concentrated juice to the water is 1:8. Here, the concentrated juice was purchased from the supplier diana food, product number CC01460001.
Next, 3% (W/V) glucose was added to the grape juice solution and allowed to stand at 95℃for 0.5 hours to obtain a grape extract. Then, 0.1% (W/V) of lager brewing yeast with accession number BCRC20271 and 0.05% (W/V) of Streptococcus thermophilus TCI633 with BCRC910636 were inoculated into the grape extract, followed by stationary culture at 30℃for 72 hours to obtain a grape fermentation broth. Here, the Brix of the initial fermentation broth of grape was 4.0.+ -. 0.5 (20 ℃) and the pH thereof was 3.0.+ -. 0.5.
Then, the grape fermentation primary liquid was concentrated under reduced pressure at about 60℃and then filtered through a sieve having a pore size of 400mesh to obtain a grape fermentation product.
Example 2: effects of combinations of probiotics of different composition on probiotics
Here, xylooligosaccharide (Xyloligosaccharide) was used, which was purchased from Shandong Biotech Co. Lactitol (lactitol) was purchased from Honghuo biotechnology. The inulin used was purchased from Cosucra. Fructooligosaccharides (fructooligosaccharides) were used commercially available from Meiji. The grape fermentate used was the grape fermentate prepared in example 1. The liquid medium used was tryptic soy broth (Tryptone Soy Broth, TSB; hereinafter TSB medium) to which 5% sheep blood (from BD) was added.
The groups were divided into a blank group, 5 experimental groups (experimental groups a to E) and 5 control groups (control groups a to E), as shown in table 1.
TABLE 1
As can be seen from table 1, the experimental medium used in the blank group was a pure liquid medium (i.e., 95% TSB medium and 5% sheep blood). The experimental culture medium used in the control groups A-E is 94% of TSB culture medium, 5% of sheep blood and 1% of single-component probiotics combination A-E, wherein the probiotics combination A-E is respectively xylooligosaccharide, lactitol, inulin, fructooligosaccharide and grape fermentation product. The experimental media used in experimental groups a-E were 94% TSB medium, 5% sheep blood and 1% probiotic compositions F-J of different composition. Here, the probiotic composition F is a 2:1:1 by weight ratio of grape fermentate, xylo-oligosaccharides and lactitol. The probiotic composition G is a grape ferment, a xylo-oligosaccharide and a fructo-oligosaccharide in a weight ratio of 2:1:1. The probiotic composition H is a grape ferment, xylo-oligosaccharide and inulin in a weight ratio of 2:1:1. The probiotic composition I is a grape ferment, lactitol and fructo-oligosaccharide in a weight ratio of 2:1:1. The probiotic composition J is a 2:1:1 weight ratio of grape ferment, lactitol and inulin.
1% of the activated Acremonium (Akkermansia muciniphila) was added to 15mL tubes containing 5mL of each group of medium, and cultured anaerobically at 37℃for 48 hours. After 48 hours of incubation, 100. Mu.L of each bacterial liquid was taken from each group of test tubes on a solid TSB medium containing 5% sheep blood, and the bacterial amounts of each group were calculated after anaerobic incubation at 37℃for 72 hours. Here, the bacterial load is expressed in Colony-forming units (CFU).
Please refer to fig. 1. The bacterial count of the blank group was 6.50log CFU, the bacterial count of the control group A was 6.75log CFU, the bacterial count of the control group B was 6.67log CFU, the bacterial count of the control group C was 6.53log CFU, the bacterial count of the control group D was 6.53log CFU, the bacterial count of the control group E was 6.88log CFU, the bacterial count of the test group A was 7.00log CFU, the bacterial count of the test group B was 6.96log CFU, the bacterial count of the test group C was 6.95log CFU, the bacterial count of the test group D was 7.11log CFU, and the bacterial count of the test group E was 7.00log CFU.
Therefore, compared with a blank group, the grape fermentation product, the xylooligosaccharide and the lactitol in the single-component probiotic combination can increase the bacterial load of the Acremonium, and the inulin and the fructooligosaccharide have no obvious effect on promoting the growth capacity of the Acremonium.
And after the probiotic components are combined based on grape fermented products, compared with a blank group, the probiotic composition formed by the multiple components can promote the growth capacity of the Acremonium and improve the bacterial load of the Acremonium. The probiotic composition having the best effect of improving the bacterial load of ackermanni was a probiotic composition D comprising a grape fermentation product, lactitol and fructooligosaccharides.
Accordingly, when the probiotic composition is composed of a grape ferment, lactitol or xylooligosaccharide as a first component, and fructooligosaccharide, xylofructose or inulin as a second component, the probiotic composition can promote the growth ability of probiotics (such as Acremonium), thereby increasing the bacterial load of the probiotics.
Example 3: effects of combinations of different proportions of prebiotics on probiotics
The prebiotic composition used here consisted of the grape ferment prepared in example 1, lactitol (from the ambitious biotechnology) and fructooligosaccharides (from Meiji). The liquid medium used was tryptic soy broth (Tryptone Soy Broth, TSB; hereinafter TSB medium) to which 5% sheep blood (from BD) was added.
The groups were divided into a blank group and 4 experimental groups (experimental groups a to D) as shown in table 2.
TABLE 2
From the above table, the weight ratio of grape ferment, lactitol and fructo-oligosaccharide of the probiotic composition a is 1:1: 1. the weight ratio of grape ferment, lactitol and fructo-oligosaccharide of the probiotic composition b is 2:1:1. the weight ratio of grape ferment, lactitol and fructo-oligosaccharide of the probiotic composition c is 1:2: 1. the weight ratio of grape ferment, lactitol and fructo-oligosaccharide in the probiotic composition d is 1:1:2.
1% of the activated Acremonium was taken, and added to 15mL tubes containing 5mL of each group of medium, respectively, and anaerobically cultured at 37℃for 48 hours. After 48 hours of incubation, 100. Mu.L of each group of bacteria were taken from each group of test tubes on a solid TSB medium containing 5% sheep blood, and the bacterial count of each group was calculated after anaerobic incubation at 37℃for 72 hours. Here, the bacterial load is expressed in colony forming units.
Referring to FIG. 2, the bacterial count of the blank group was 6.50log CFU, the bacterial count of the test group A was 6.92log CFU, the bacterial count of the test group B was 7.11log CFU, the bacterial count of the test group C was 6.77log CFU, and the bacterial count of the test group d was 6.66log CFU.
Compared with the blank group, the probiotic compositions a-d formed by grape fermentation products, lactitol and fructo-oligosaccharides can effectively promote the growth capacity of the Acremonium and improve the bacterial load of the Acremonium. And, when the probiotic composition is 50% of grape ferment, 25% of lactitol and 25% of fructooligosaccharides, the probiotic composition can significantly promote the growth capacity of ackermannin bacteria by at least 1.1 times.
Based on this, the probiotic combinations of grape fermentate, lactitol and fructooligosaccharides, in whatever proportions, are effective in enhancing the growth of probiotics (e.g., ackermannia). Wherein, compared with other ratios, when the ratio of grape ferment, lactitol and fructo-oligosaccharide is 2:1:1, the effect of the probiotic combination on improving the growth capacity of probiotics (such as ackermanni) is obviously better.
Example 4: human body experiment
4-1, experimental design
7 subjects were provided with capsules each containing 400mg of the probiotic composition consisting of the grape ferment prepared in example 1, lactitol (from the ambibiosis technology) and fructooligosaccharides (from Meiji) in a weight ratio of 2:1:1, one capsule per day, and for 2 weeks. In other words. The daily dose per person was 400mg of the probiotic composition. Each subject was tested at week 0 (i.e., before administration) and week 2 (i.e., after administration for 2 weeks).
4-2, intestinal bacteria phase analysis of the subject
Feces were collected from 7 subjects before (i.e., week 0) and after (i.e., week 2) the probiotic composition was administered, and were subjected to fecal phase NGS analysis (sequencing position: 16s rRNA V3-V4) by the company of tuer biotechnology, inc (BIOTOOLS) to determine the growth capacity of the intestinal bacterial phase.
The bacterial species of the bacterial phase analyzed herein was Kmaminophilia (Akkermansia muciniphila; hereinafter referred to as AKK bacteria) and Bifidobacterium (Bifidobacterium).
Please refer to fig. 3. The average number of AKK bacteria at week 0 in 7 subjects was regarded as 1, and the ratio of the average number of AKK bacteria at week 2 in 7 subjects was calculated based on the result. Here, the average AKK bacteria count ratio at week 2 of 7 subjects was 2.56. That is, 7 subjects showed 2 weeks after continuously taking the probiotic composition, the bacterial load of AKK bacteria in the intestinal tract was increased by 2.56 times, and the metabolite of AKK bacteria could suppress appetite of the host and induce the expression of FIAF (Fasting-Induced Adipose Factor) gene of the host, thereby reducing the fat storage ability of the host. In addition, when the bacterial load of AKK bacteria in the intestinal tract is increased, obesity caused by high-fat diet can be reversed, and the concentration of lipopolysaccharide of harmful bacteria in blood can be reduced, so that chronic inflammation can be reduced, and insulin resistance can be reduced. Therefore, by taking the probiotic composition comprising the fermented grape product, lactitol and fructo-oligosaccharide, the bacterial load of AKK bacteria in the intestinal tract of a user can be effectively increased, so that various effects of slimming, reducing chronic inflammation, relieving insulin resistance and the like are achieved.
Please refer to fig. 4. The average bifidobacterium count at week 0 of 7 subjects was regarded as 1, and the average bifidobacterium count ratio at week 2 of 7 subjects was converted based on this. Here, the average bifidobacterium cell count ratio at week 2 of 7 subjects was 3.84. That is, 7 subjects had a 3.84-fold increase in bifidobacteria in their intestinal tract after 2 weeks of continuous administration of the probiotic composition. In addition, when the bacterial load of the bifidobacteria in the intestinal tract of the human body is improved, the bifidobacteria serving as the physiological beneficial bacteria can improve the biological barrier of the human body, provide nutrition for the human body, enhance the immunity of the human body, improve the gastrointestinal tract health of the human body and improve the anti-aging capability of the human body, thereby being capable of making the human body healthy. Therefore, by taking the probiotic composition consisting of the grape ferment, the lactitol and the fructo-oligosaccharide, the bacterial load of bifidobacteria in the intestinal tract of a user can be effectively increased, so that the bacterial load of intestinal probiotics of a receptor is increased, and various physiological functions beneficial to health, such as increasing biological barrier of the receptor, providing nutrition for the receptor, enhancing immunity of the receptor, improving gastrointestinal health of the receptor, improving anti-aging capability of the receptor and the like, are achieved.
4-3, analysis of CLDN3 protein content in blood of a subject
7 subjects were each 6mL of venous blood was collected using a purple-head blood collection tube containing EDTA anticoagulant before (i.e., week 0) and after (i.e., week 2) administration of the probiotic composition, and were committed to the Dajiang GENE (TCI GENE) for analysis of the expression level of sulfur-containing compounds and total Glutathione (GSH) in the blood. Here, the sulfur compound detected is f-thiol (Thiols). f-mercaptan and total glutathione are indicators of the antioxidant capacity of the human body. When the content of f-thiol or glutathione is increased, this represents an increase in the ability to scavenge free radicals in vivo, thereby enhancing the ability to resist oxidative stress damage to cells.
Please refer to fig. 5. The average f-thiol content in blood was 322.29 μg/mL for 7 subjects at week 0, and increased to 377.86 μg/mL after administration of the 2 Zhou Yisheng mass composition. That is, the average f-thiol content in blood increased by 55.57. Mu.g/mL (corresponding to a 17.2% increase) after administration of the 2.2 Zhou Yisheng mass composition. It is known that the f-mercaptan content is effectively increased by taking the probiotic composition, so that the free radical scavenging capacity and the antioxidation capacity in the body are improved.
Please refer to fig. 6. The average total glutathione content in blood was 1380. Mu. Mol/L in 7 subjects at week 0, and was increased to 1449. Mu. Mol/L after taking 2 Zhou Yisheng mass of the composition. That is, after administration of the 2 Zhou Yisheng substance composition, the average total glutathione content in the blood increased by 69. Mu. Mol/L (corresponding to 5% increase). It is known that the total glutathione content can be effectively increased by taking the probiotic composition, thereby improving the capability of scavenging free radicals in vivo and improving the antioxidant capability.
In summary, the probiotic composition prepared with the grape fermentation according to any of the embodiments of the present invention may be used to promote the growth ability of ackermannia, wherein the probiotic composition comprises the grape fermentation, lactitol or xylooligosaccharide as a first component, and fructooligosaccharide, xylooligosaccharide or inulin as a second component, and the weight ratio of the grape fermentation, the first component and the second component is 1-2:1-2:1-2. In some embodiments, the probiotic composition prepared with a grape ferment, lactitol and fructooligosaccharides may be used to promote intestinal health and/or enhance the antioxidant capacity of the recipient. Wherein the weight ratio of grape ferment, lactitol and fructo-oligosaccharide contained in the probiotic composition is 1-2:1-2:1-2. In some embodiments, the probiotic composition may promote intestinal health of the recipient by promoting growth of probiotics (such as ackermann and bifidobacteria). In some embodiments, the probiotic composition may increase the antioxidant capacity of the recipient by increasing the level of sulfur-containing compounds (e.g., thiols) and total glutathione (total Glutathione) in the recipient.
Of course, the present invention is capable of other various embodiments and its several details are capable of modification and variation in light of the present invention by one skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (11)
1. A probiotic composition comprising:
grape fermentation;
a first component which is lactitol or xylooligosaccharide; and
a second component which is fructo-oligosaccharide, xylo-oligosaccharide or inulin;
wherein the first component is different from the second component;
wherein the weight ratio of the grape ferment to the first component to the second component is 1-2:1-2:1-2.
2. The probiotic composition according to claim 1, wherein the weight ratio of the grape ferment, the first ingredient and the second ingredient is 2:1:1.
3. the probiotic composition according to claim 1, wherein the first ingredient is the lactitol and the second ingredient is the fructooligosaccharide.
4. A probiotic composition according to any one of claims 1 to 3, for promoting the growth capacity of ackermanni (Akkermansia muciniphila).
5. Use of a grape ferment for preparing a probiotic composition for promoting intestinal health of a recipient, wherein the probiotic composition comprises a grape ferment, lactitol and fructooligosaccharides, wherein the weight ratio of the grape ferment, the lactitol and the fructooligosaccharides is 1-2:1-2:1-2.
6. The use according to claim 5, wherein the weight ratio of the grape ferment, the lactitol and the fructooligosaccharides is 2:1:1.
7. the use of claim 5, wherein promoting intestinal health of the subject comprises promoting growth of probiotics including ackermanni (Akkermansia muciniphila) and bifidobacteria (bifidobacteria).
8. Use of a grape ferment for preparing a probiotic composition for enhancing the antioxidant capacity of a recipient, wherein the probiotic composition comprises a grape ferment, lactitol and fructooligosaccharides, wherein the weight ratio of the grape ferment, the lactitol and the fructooligosaccharides is 1-2:1-2:1-2.
9. The use according to claim 8, wherein the weight ratio of the grape ferment, the lactitol and the fructooligosaccharides is 2:1:1.
10. the use of claim 8, wherein the probiotic composition is used to increase the level of sulfur-containing compounds and total glutathione (total Glutathione) in the subject.
11. The use according to claim 10, wherein the sulfur-containing compound is a thiol (Thiols) type compound.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210103501.7A CN116548609A (en) | 2022-01-27 | 2022-01-27 | Prebiotic composition and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210103501.7A CN116548609A (en) | 2022-01-27 | 2022-01-27 | Prebiotic composition and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116548609A true CN116548609A (en) | 2023-08-08 |
Family
ID=87495222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210103501.7A Pending CN116548609A (en) | 2022-01-27 | 2022-01-27 | Prebiotic composition and use thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116548609A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130171204A1 (en) * | 2011-12-30 | 2013-07-04 | Vets Plus, Inc. | Soft food composition with probiotics and prebiotics for masking medications |
CA2981834A1 (en) * | 2017-05-31 | 2018-11-30 | Stephen Bruce Roman | Plant extract composition and method to improve gut health |
US20210023159A1 (en) * | 2019-07-22 | 2021-01-28 | Tci Co., Ltd. | Method for promoting growth of akkermansia muciniphila using musa ferments |
TW202114542A (en) * | 2019-10-07 | 2021-04-16 | 大江生醫股份有限公司 | Prebiotic composition for promoting growth ofclostridium butyricumand uses thereof |
CN112708590A (en) * | 2019-10-24 | 2021-04-27 | 大江生医股份有限公司 | Composition for promoting growth of Achiminotropic bacteria and application thereof |
CN112825990A (en) * | 2019-11-01 | 2021-05-25 | 大江生医股份有限公司 | Use of red grape fermented juice for preparing composition for improving skin condition |
-
2022
- 2022-01-27 CN CN202210103501.7A patent/CN116548609A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130171204A1 (en) * | 2011-12-30 | 2013-07-04 | Vets Plus, Inc. | Soft food composition with probiotics and prebiotics for masking medications |
CA2981834A1 (en) * | 2017-05-31 | 2018-11-30 | Stephen Bruce Roman | Plant extract composition and method to improve gut health |
US20210023159A1 (en) * | 2019-07-22 | 2021-01-28 | Tci Co., Ltd. | Method for promoting growth of akkermansia muciniphila using musa ferments |
CN112274577A (en) * | 2019-07-22 | 2021-01-29 | 大江生医股份有限公司 | Use of a composition comprising a fermentation of a Musa species and a probiotic composition |
TW202104583A (en) * | 2019-07-22 | 2021-02-01 | 大江生醫股份有限公司 | Prebiotic composition for promoting growth of akkermansia muciniphila |
TW202114542A (en) * | 2019-10-07 | 2021-04-16 | 大江生醫股份有限公司 | Prebiotic composition for promoting growth ofclostridium butyricumand uses thereof |
CN112708590A (en) * | 2019-10-24 | 2021-04-27 | 大江生医股份有限公司 | Composition for promoting growth of Achiminotropic bacteria and application thereof |
CN112825990A (en) * | 2019-11-01 | 2021-05-25 | 大江生医股份有限公司 | Use of red grape fermented juice for preparing composition for improving skin condition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7993903B2 (en) | Cholesterol absorption inhibitor | |
TWI645854B (en) | Lactobacillus plantarum TCI378 and its application in reducing fat and improving gastrointestinal function | |
CN112402464B (en) | Compound probiotic composition beneficial to type 2diabetes patients | |
WO2020211831A1 (en) | Functional food of probiotic preparation having blood glucose lowering effect | |
KR20160132050A (en) | Novel lactobacillus paracasei strain | |
CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
CN112970990A (en) | Probiotic solid beverage with weight-losing and lipid-lowering effects and preparation process thereof | |
CN116076728B (en) | Composition for promoting growth of bifidobacteria | |
CN112274577B (en) | Use of a composition comprising a fermentation of a Musa species and a probiotic composition | |
CN108795823B (en) | It is a kind of improve women pregnant and lying-in women's intestinal flora probiotics cultural method and application | |
CN110638841A (en) | Probiotics and prebiotics compound preparation, preparation method and application thereof | |
CN112694989A (en) | Lactobacillus paracasei X11 and composition thereof constipation composite preparation and dairy product | |
TWI817342B (en) | Prebiotic composition and uses thereof | |
CN116548609A (en) | Prebiotic composition and use thereof | |
TWI764295B (en) | Lactobacillus gasseri tci943 or its metabolite and use of lactobacillus gasseri tci943 for improving skin condition | |
JP7396798B2 (en) | Composition for promoting intestinal butyrate production | |
US20230144246A1 (en) | Probiotic composition and its method for improving intestinal tract of subject in need thereof | |
TWI835021B (en) | Probiotic composition and its use | |
CN116076711A (en) | Prebiotic composition and use thereof | |
US20240009261A1 (en) | Prebiotic compositions and method for weight loss by using the same | |
KR102501958B1 (en) | A novel Lactobacillus fermentum strain derived from Panax ginsengand the use thereof | |
KR102202092B1 (en) | Weissella koreensis nd824 strain having improved productivity of ornithine and composition comprisingng the same | |
KR20240118626A (en) | Composition for improving intestinal function comprising Lactiplantibacillus plantarum Y7 | |
CN118516248A (en) | Bifidobacterium animalis subspecies BX-186 for relieving adverse effects of semeglutide | |
CN115029284A (en) | Active probiotics and application thereof in food |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |